EUPATI workshop, Dublin, 23rd April 2015
EUPATI in Spain
Done, doing, to be done
Done
 Spanish NLT working until 2013
 Four partners: GEPAC, FEDE (patients);
Universidad Complutense (Academia);
Farmaindustria (Pharma industry)
 GEPAC: Spanish cancer patients group
 FEDE: Spanish diabetes patients federation
 Universidad Complutense:
The main university in Spain
 Farmaindustria: National Trade Association of the Spanish based
pharmaceutical industry
 Some changes suffered in the NLT members during 2013.
Done
 Launch of the Spanish ENP
 Key moment: The appointment of Laura Kavanagh as ENP
coordinator in EUPATI consortium.
 First step: presentation event of EUPATI in Spain
 04 November 2014: Event in Madrid with around 100 participants
representing patient organizations and pharma companies
In the event, Concha
Prieto, from AEMPS, the
Spanish medicines
agency, delivered a
speech on patient
involvement.
Vídeo of the event.
Done
 Launch of the Spanish ENP
 Second step: contact with the Government
 Two meetings: During 2014, members of the NLT hold two meetings
with representatives of the Spanish Health Ministry.
 In July, second meeting with Paloma Casado, vice-Director in the
Health Ministry, in charge of relations with patients organizations. In
our opinion, they are still not ready to engage with EUPATI until they
learn more about the role of industry and the influence on patients
within the project.
Done
 Launch of the Spanish ENP
 Third step: creation of an Executive Board to manage the ENP
 December 2014: Meeting with all the entities interested in EUPATI.
 January 2015: First meeting of this Board, with 9 organizations:
6 patients associations, 2 representatives of academia and 1
member from the pharma companies.
 GEPAC
 FEDE
 Conartritis
 Lupus Madrid
 Menudos Corazones
 ACCU
 Universidad Complutense de Madrid
 Hospital Sant Joan de Deu de Barcelona
 Farmaindustria
Doing
 Spreading the news
 Activities in 2015:
 Rare diseases event in Hospital Sant Joan de Deu in Barcelona (27
February)
 8th Annual Conference of Biomedical Research hosted by
Farmaindustria in Madrid (24 March)
 EUPATI training course meeting in Barcelona (1 April)
 SEMERGEN congress in Toledo (April)
 R&D Pfizer forum in Madrid (April)
Doing
 Programming our activity
 The Spanish ENP is developing an action plan with three axis:
 Contents. Developed by EUPATI or by third parties but aligned with
EUPATI objectives.
 Activities. Thinking of new
educative initiatives and
organising events.
 Communication. Spreading
the news vaa mass media
and social networks (twitter,
facebook, etc…).
Doing
 Working with stakeholders
 EUPATI is collaborating with two pharma companies (MSD and
Novartis) to participate in educational activities during 2015. Some
more companies are interested in future joint ventures.
 The ENP is going to ask AEMPS (the Spanish medicines agency) to
collaborate in future informative and educational activities. This can be
a more effective way or working together with de Government, better
than the Health Ministry.
 The two main patients organizations in Spain (Foro Español de
Pacientes and Plataforma de Organizaciones de Pacientes) are
represented in the ENP and informed about EUPATI activities in
Spain.
To be done
 EUPATI training course
 Just one Spanish student in the on-going course: Begoña Nafría, also
member of the ENP. She will be the first EUPATI tools teacher in
Spain.
 20 Spanish candidates for the second edition of the course.
 Waiting for the publication of EUPATI course material in English. The
team will then look into how this might be used in Spain, and whether
these materials could be translated and used to mobilise patient
organisations and organize trainings in Spain, hopefully together with
AEMPS, the Spanish Medicines Agency.
To be done
 EUPATI toolbox
 Waiting for the first educational contents provided by EUPATI before
the end of 2015.
 Trying to hold a main event at the end of the year to present these
materials. It could be the second annual EUPATI workshop in Spain,
after the first one in November 2014 which launched the National
Platform.
New landscape
 New regulation in Spain (probably approved this June) will allow
patient advocates to participate in ethics committees, in the design of
clinical trials and in the writing of therapeutic recommendations.
 EUPATI objectives, training and contents will be crucial in these new
areas of the therapeutic innovation process, where researchers,
patients, industry and authorities will have to collaborate all together.
 The Spanish ENP will be ready to disseminate the EUPATI materials
and to collaborate in this new paradigm

More Related Content

PPTX
G3 report from breakout group 3
PPTX
G1 report from breakout group 1
PPTX
EUPATI patient expert training course and its relevance for patient involvement
PPTX
G2 report from breakout group 2
PPTX
Introduction to the breakout sessions & case studies presentations
PPTX
Introduction to the workshop and EUPATI update
PPTX
Communication & social media
PPTX
G4 report from breakout group 4
G3 report from breakout group 3
G1 report from breakout group 1
EUPATI patient expert training course and its relevance for patient involvement
G2 report from breakout group 2
Introduction to the breakout sessions & case studies presentations
Introduction to the workshop and EUPATI update
Communication & social media
G4 report from breakout group 4

What's hot (20)

PPTX
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
PPTX
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
PPTX
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
PPT
Reaching a public audience on medicines development: Anna Zawada
PPTX
What were the success factors in this morning good practices examples, what a...
PPTX
EUPATI’s framework on Informing the “health-interested” public about medicine...
PPTX
European Patients Academy - Presentation of Jan Geissler at EPF AGM
PPTX
What do people think about medicines research and development? (Starling, EUP...
PPTX
How to raise interest in medicines development: Results from Workgroup 1
PPT
Introduction to the breakout sessions & case studies presentations
PPTX
EUPATI Launch Meeting - Jan Geissler
PPT
Rare Disease Day: Discussion of a good practice example: Mavris
PPT
Workshop 2 - "Presentation of the concept, definitions and terminology"
PDF
Jornadas #PatientInHTA · Iñaki Imaz
PPTX
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
PPT
Workshop 6 - "Training package on RD for medical students"
PDF
Eupati toolbox march 2016
PPT
Workshop 5 - "Presentation of Social Challenges of RD patients in the Joint A...
PPTX
Future Health Summit - Dr Derick Mitchell - May 26th 2016
PPTX
Derick mitchell, IPPOSI
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...
Reaching a public audience on medicines development: Anna Zawada
What were the success factors in this morning good practices examples, what a...
EUPATI’s framework on Informing the “health-interested” public about medicine...
European Patients Academy - Presentation of Jan Geissler at EPF AGM
What do people think about medicines research and development? (Starling, EUP...
How to raise interest in medicines development: Results from Workgroup 1
Introduction to the breakout sessions & case studies presentations
EUPATI Launch Meeting - Jan Geissler
Rare Disease Day: Discussion of a good practice example: Mavris
Workshop 2 - "Presentation of the concept, definitions and terminology"
Jornadas #PatientInHTA · Iñaki Imaz
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
Workshop 6 - "Training package on RD for medical students"
Eupati toolbox march 2016
Workshop 5 - "Presentation of Social Challenges of RD patients in the Joint A...
Future Health Summit - Dr Derick Mitchell - May 26th 2016
Derick mitchell, IPPOSI
Ad

Viewers also liked (20)

PPTX
Patient involvement prior to regulatory Scientific Advice
PPTX
Present progressiveana
PPTX
Present progressivenvo
PPTX
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
PPTX
EUPATI 2013 Conference: Welcome and Introduction
PDF
Delivering Professional IT Services; Mind the gap of Cultural Risks
PPT
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
PPTX
Mini-Course Starter Kits
PPTX
Patients’ voice in access decisions
PPT
Health Technology Assessment
PPTX
Protection of subjects and informed consent - the clinical trials regulation ...
PPTX
Blood basics in Dentistry
PPTX
The patients' contribution to ethics committees in the Netherlands
PDF
Travel 2.0: Como adaptar la web de su hotel a las ultimas tendencias de Inter...
PDF
Twitter at E-Tourism Summit
PPT
Castilla en época de isabel i corregido
PPT
La CéLula
DOCX
Actividad 2
PDF
Training Caravan: Stefano Balbi [Aniturri BHI and Ikasbidea Ikastola] 20150316
PDF
061127
Patient involvement prior to regulatory Scientific Advice
Present progressiveana
Present progressivenvo
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
EUPATI 2013 Conference: Welcome and Introduction
Delivering Professional IT Services; Mind the gap of Cultural Risks
Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013
Mini-Course Starter Kits
Patients’ voice in access decisions
Health Technology Assessment
Protection of subjects and informed consent - the clinical trials regulation ...
Blood basics in Dentistry
The patients' contribution to ethics committees in the Netherlands
Travel 2.0: Como adaptar la web de su hotel a las ultimas tendencias de Inter...
Twitter at E-Tourism Summit
Castilla en época de isabel i corregido
La CéLula
Actividad 2
Training Caravan: Stefano Balbi [Aniturri BHI and Ikasbidea Ikastola] 20150316
061127
Ad

Similar to Introduction to the break out sessions & case studies presentations (20)

PPTX
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
PPTX
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
PDF
Jornadas #PatientInHTA · Tamas Bereczky
PPTX
ISPOR Eupati meeting - Dr Derick Mitchell - November 2017
PPTX
EUPATI Launch Meeting - Per Spindler
PPTX
The benefits of patient involvement in research and development (RE:ACT Congr...
PPTX
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
PPTX
The emergence of the e-patient
PPTX
Tripartite dimension of interaction of patients, regulators and industry (Jan...
PPTX
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
PPTX
EUPATI guidances for interaction between Patient organisations and other stak...
PPTX
CHESS Connected Health training network - Derick Mitchell - August 2016
PPT
Involvepresentation
PPTX
The role of patients and healthcare providers in translational medicine
PPTX
Alpha One Conference - IPPOSI
PPTX
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
PPTX
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
PPTX
Patient involvement in medicines development – the views of patients and key ...
PPTX
EUPATI Launch Meeting - Klingmann
PPTX
Croi Galway - Derick Mitchell - July 2016
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
Jornadas #PatientInHTA · Tamas Bereczky
ISPOR Eupati meeting - Dr Derick Mitchell - November 2017
EUPATI Launch Meeting - Per Spindler
The benefits of patient involvement in research and development (RE:ACT Congr...
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...
The emergence of the e-patient
Tripartite dimension of interaction of patients, regulators and industry (Jan...
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
EUPATI guidances for interaction between Patient organisations and other stak...
CHESS Connected Health training network - Derick Mitchell - August 2016
Involvepresentation
The role of patients and healthcare providers in translational medicine
Alpha One Conference - IPPOSI
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
Patient involvement in medicines development – the views of patients and key ...
EUPATI Launch Meeting - Klingmann
Croi Galway - Derick Mitchell - July 2016

More from EUPATI (6)

PPTX
Drug development and treatment strategies may go hand in hand.
PPT
Informed consent for incapacitated patients and in emergency situations.
PPTX
Good practices in patient involvement in HTA
PPTX
Patients' involvement in ethics committees. A view from Austria.
PPTX
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
PPTX
Researching information needs and beliefs of patients, professionals and the ...
Drug development and treatment strategies may go hand in hand.
Informed consent for incapacitated patients and in emergency situations.
Good practices in patient involvement in HTA
Patients' involvement in ethics committees. A view from Austria.
Translating Patient Needs into Robust, Easily Accessible Quality Materials -...
Researching information needs and beliefs of patients, professionals and the ...

Recently uploaded (20)

PDF
Nematodes - by Sanjan PV 20-52.pdf based on all aspects
PDF
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in an...
PPTX
ACUTE PANCREATITIS combined.pptx.pptx in kids
PPTX
Type 2 Diabetes Mellitus (T2DM) Part 3 v2.pptx
PDF
heliotherapy- types and advantages procedure
PPTX
presentation on dengue and its management
PPT
ANTI-HYPERTENSIVE PHARMACOLOGY Department.ppt
PDF
NCCN CANCER TESTICULAR 2024 ...............................
PDF
Demography and community health for healthcare.pdf
PPT
fiscal planning in nursing and administration
PPTX
FORENSIC MEDICINE and branches of forensic medicine.pptx
PPTX
ANTI BIOTICS. SULPHONAMIDES,QUINOLONES.pptx
PPTX
This book is about some common childhood
PPTX
Surgical anatomy, physiology and procedures of esophagus.pptx
PDF
Diabetes mellitus - AMBOSS.pdf
PDF
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
PPTX
Phamacology Presentation (Anti cance drugs).pptx
PPTX
Diabetic Foot- Foot Ulcer Classification.pptx
PPTX
IMMUNITY ... and basic concept mds 1st year
PPTX
Computed Tomography: Hardware and Instrumentation
Nematodes - by Sanjan PV 20-52.pdf based on all aspects
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in an...
ACUTE PANCREATITIS combined.pptx.pptx in kids
Type 2 Diabetes Mellitus (T2DM) Part 3 v2.pptx
heliotherapy- types and advantages procedure
presentation on dengue and its management
ANTI-HYPERTENSIVE PHARMACOLOGY Department.ppt
NCCN CANCER TESTICULAR 2024 ...............................
Demography and community health for healthcare.pdf
fiscal planning in nursing and administration
FORENSIC MEDICINE and branches of forensic medicine.pptx
ANTI BIOTICS. SULPHONAMIDES,QUINOLONES.pptx
This book is about some common childhood
Surgical anatomy, physiology and procedures of esophagus.pptx
Diabetes mellitus - AMBOSS.pdf
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
Phamacology Presentation (Anti cance drugs).pptx
Diabetic Foot- Foot Ulcer Classification.pptx
IMMUNITY ... and basic concept mds 1st year
Computed Tomography: Hardware and Instrumentation

Introduction to the break out sessions & case studies presentations

  • 1. EUPATI workshop, Dublin, 23rd April 2015 EUPATI in Spain Done, doing, to be done
  • 2. Done  Spanish NLT working until 2013  Four partners: GEPAC, FEDE (patients); Universidad Complutense (Academia); Farmaindustria (Pharma industry)  GEPAC: Spanish cancer patients group  FEDE: Spanish diabetes patients federation  Universidad Complutense: The main university in Spain  Farmaindustria: National Trade Association of the Spanish based pharmaceutical industry  Some changes suffered in the NLT members during 2013.
  • 3. Done  Launch of the Spanish ENP  Key moment: The appointment of Laura Kavanagh as ENP coordinator in EUPATI consortium.  First step: presentation event of EUPATI in Spain  04 November 2014: Event in Madrid with around 100 participants representing patient organizations and pharma companies In the event, Concha Prieto, from AEMPS, the Spanish medicines agency, delivered a speech on patient involvement. Vídeo of the event.
  • 4. Done  Launch of the Spanish ENP  Second step: contact with the Government  Two meetings: During 2014, members of the NLT hold two meetings with representatives of the Spanish Health Ministry.  In July, second meeting with Paloma Casado, vice-Director in the Health Ministry, in charge of relations with patients organizations. In our opinion, they are still not ready to engage with EUPATI until they learn more about the role of industry and the influence on patients within the project.
  • 5. Done  Launch of the Spanish ENP  Third step: creation of an Executive Board to manage the ENP  December 2014: Meeting with all the entities interested in EUPATI.  January 2015: First meeting of this Board, with 9 organizations: 6 patients associations, 2 representatives of academia and 1 member from the pharma companies.  GEPAC  FEDE  Conartritis  Lupus Madrid  Menudos Corazones  ACCU  Universidad Complutense de Madrid  Hospital Sant Joan de Deu de Barcelona  Farmaindustria
  • 6. Doing  Spreading the news  Activities in 2015:  Rare diseases event in Hospital Sant Joan de Deu in Barcelona (27 February)  8th Annual Conference of Biomedical Research hosted by Farmaindustria in Madrid (24 March)  EUPATI training course meeting in Barcelona (1 April)  SEMERGEN congress in Toledo (April)  R&D Pfizer forum in Madrid (April)
  • 7. Doing  Programming our activity  The Spanish ENP is developing an action plan with three axis:  Contents. Developed by EUPATI or by third parties but aligned with EUPATI objectives.  Activities. Thinking of new educative initiatives and organising events.  Communication. Spreading the news vaa mass media and social networks (twitter, facebook, etc…).
  • 8. Doing  Working with stakeholders  EUPATI is collaborating with two pharma companies (MSD and Novartis) to participate in educational activities during 2015. Some more companies are interested in future joint ventures.  The ENP is going to ask AEMPS (the Spanish medicines agency) to collaborate in future informative and educational activities. This can be a more effective way or working together with de Government, better than the Health Ministry.  The two main patients organizations in Spain (Foro Español de Pacientes and Plataforma de Organizaciones de Pacientes) are represented in the ENP and informed about EUPATI activities in Spain.
  • 9. To be done  EUPATI training course  Just one Spanish student in the on-going course: Begoña Nafría, also member of the ENP. She will be the first EUPATI tools teacher in Spain.  20 Spanish candidates for the second edition of the course.  Waiting for the publication of EUPATI course material in English. The team will then look into how this might be used in Spain, and whether these materials could be translated and used to mobilise patient organisations and organize trainings in Spain, hopefully together with AEMPS, the Spanish Medicines Agency.
  • 10. To be done  EUPATI toolbox  Waiting for the first educational contents provided by EUPATI before the end of 2015.  Trying to hold a main event at the end of the year to present these materials. It could be the second annual EUPATI workshop in Spain, after the first one in November 2014 which launched the National Platform.
  • 11. New landscape  New regulation in Spain (probably approved this June) will allow patient advocates to participate in ethics committees, in the design of clinical trials and in the writing of therapeutic recommendations.  EUPATI objectives, training and contents will be crucial in these new areas of the therapeutic innovation process, where researchers, patients, industry and authorities will have to collaborate all together.  The Spanish ENP will be ready to disseminate the EUPATI materials and to collaborate in this new paradigm